ICU Antipsychotic Exposure Linked to Fewer Catatonia-Free Days

Catatonia is increasingly recognized as an independent, severe neuropsychiatric syndrome that complicates a wide range of medical and psychiatric conditions [1]. While clinicians often rely on antipsychotic medications to manage acute agitation and delirium in hospital settings, these dopamine-blocking agents carry well-documented risks, including neuroleptic malignant syndrome and antipsychotic-induced catatonia [2, 3]. The exact pathophysiological mechanisms driving catatonia remain complex, but evidence points toward dopamine receptor blockade as a significant precipitating factor [2, 4]. Despite these known risks, the direct impact of routine antipsychotic administration on catatonia development in the intensive care unit has remained poorly quantified. A prospective cohort study of 270 critically ill patients now offers specific clinical data, demonstrating that antipsychotic exposure is associated with a 74% reduction in the odds of experiencing more catatonia-free days (the number of days a patient remains alive and without catatonic symptoms) within the first five days of admission, with higher cumulative doses reducing these odds by 97% [5].